Changes for page AstraZeneca
Last modified by Wilton Risenhoover on 2022/07/06 01:12
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
-
Attachments (0 modified, 0 added, 2 removed)
Details
- Page properties
-
- Content
-
... ... @@ -40,7 +40,7 @@ 40 40 * 1new molecular entity approval 41 41 42 42 43 -[[image:AZN 4.png||alt="AZN2.png"]]43 +[[image:AZN2.png]] 44 44 45 45 46 46 === Cambridge === ... ... @@ -67,34 +67,36 @@ 67 67 Looking to the future, Gothenburg has initiated the creation of a new, global cluster for health and life sciences, as part of the GoCo Health Innovation City project, which includes the Gothenburg BioVentureHub. There are currently more than 30 external companies and one academic group co-locating with AstraZeneca at the heart of the Gothenburg site. By facilitating interactions between drug, device, diagnostics and digital health companies, AstraZeneca is creating a dynamic, creative and fertile environment for helping unlock the power of what science can do. 68 68 69 69 70 -[[image:AZN2.png]] 71 71 72 - 73 73 = Therapy Area = 74 74 75 75 == Oncology == 76 76 77 -AstraZeneca has a bold ambition to provide cures for cancer in every form. AstraZeneca is following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world. {{footnote}}https://www.astrazeneca.com/our-therapy-areas/oncology.html{{/footnote}}75 +AstraZeneca has a bold ambition to provide cures for cancer in every form. AstraZeneca is following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world. 78 78 77 +[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/oncology.html>>url:https://www.astrazeneca.com/our-therapy-areas/oncology.html]] 79 79 80 80 The company's Oncology strategy is built with one goal in mind – to push the boundaries of science to change the practice of medicine and transform the lives of patients living with cancer. The company's broad pipeline of next-generation medicines, together with its focus on excellence in execution, are aimed at expanding treatment options and improving outcomes for patients with solid tumours and haematological cancers. 81 81 82 82 The company focus on four strategic priorities: 83 83 84 -* Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies 85 -* Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients 86 -* Building expertise and leadership in the most prevalent and highest mortality rate tumour types 87 -* Delivering across its global footprint 83 +•Pioneering research across six scientific platforms: Tumour drivers and resistance; Immuno-oncology; DNA damage response, Antibody drug conjugates, Epigenetics and Cell therapies 88 88 85 +•Advancing innovative clinical strategies to treat early stages of disease and relapsed or refractory patients 89 89 90 - **keydisease areas**87 +•Building expertise and leadership in the most prevalent and highest mortality rate tumour types 91 91 89 +•Delivering across its global footprint 90 + 91 +key disease areas 92 + 92 92 The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients. 93 93 95 +BioPharmaceuticals 94 94 95 - ==BioPharmaceuticals==97 +Through its work in BioPharmaceuticals, the company want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. There remains a huge unmet need in treating people with chronic diseases. The company's ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them. 96 96 97 - Through itsork in BioPharmaceuticals, thecompany want totransformhealthcare, change the livesofbillions ofpeople for the betterand address some of the biggest healthcarechallenges facing humankind. There remains a huge unmetneedin treating people with chronic diseases.The company's ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.{{footnote}}https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html{{/footnote}}99 +[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html>>url:https://www.astrazeneca.com/our-therapy-areas/biopharmaceuticals.html]] 98 98 99 99 100 100 BioPharmaceuticals is responsible for its key therapy areas of Cardiovascular, Renal & Metabolism and Respiratory & Immunology. ... ... @@ -105,16 +105,16 @@ 105 105 106 106 The company will achieve its ambition of transforming healthcare through its talented teams and partners using scientific, medical and commercial innovation. 107 107 110 +BioPharmaceuticals Business Unit 108 108 109 -**BioPharmaceuticals Business Unit** 110 - 111 111 The company's commercial teams are transforming how the company bring products to market; engage with patients, healthcare providers and health systems; and deliver healthcare solutions that support them. 112 112 113 113 114 - ==Cardiovascular, Renal and Metabolism==115 +Cardiovascular, Renal and Metabolism 115 115 116 -The company aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas {{footnote}}https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html{{/footnote}}117 +The company aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas 117 117 119 +[[https:~~/~~/www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html>>url:https://www.astrazeneca.com/our-therapy-areas/cardiovascular-renal-and-metabolism.html]] 118 118 119 119 Cardiovascular, Renal & Metabolism (CVRM) diseases are the leading causes of death across the globe, killing more than 20 million people each year. 120 120
- AZN4.png
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.AsifF - Size
-
... ... @@ -1,1 +1,0 @@ 1 -211.9 KB - Content
- AZN5.jpg
-
- Author
-
... ... @@ -1,1 +1,0 @@ 1 -XWiki.AsifF - Size
-
... ... @@ -1,1 +1,0 @@ 1 -283.1 KB - Content